Brokerages Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) PT at $29.00

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $29.00.

Several research analysts have recently issued reports on KMTS shares. Piper Sandler upped their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, December 12th. The Goldman Sachs Group set a $24.00 price target on shares of Kestra Medical Technologies in a research report on Friday, January 16th. BTIG Research began coverage on Kestra Medical Technologies in a report on Tuesday, November 18th. They set a “buy” rating and a $32.00 price objective on the stock. Wells Fargo & Company lifted their target price on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a report on Friday, December 12th.

Insider Buying and Selling

In other news, insider Traci S. Umberger sold 10,500 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the completion of the sale, the insider directly owned 136,633 shares of the company’s stock, valued at approximately $3,646,734.77. This represents a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00. Following the transaction, the insider owned 379,786 shares in the company, valued at approximately $9,722,521.60. This trade represents a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 55,500 shares of company stock valued at $1,405,095. 3.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Several large investors have recently modified their holdings of KMTS. Millennium Management LLC acquired a new position in Kestra Medical Technologies in the 1st quarter valued at $11,036,000. Woodline Partners LP purchased a new stake in shares of Kestra Medical Technologies in the first quarter valued at about $2,510,000. Jane Street Group LLC acquired a new position in shares of Kestra Medical Technologies during the first quarter worth about $756,000. Jennison Associates LLC raised its holdings in Kestra Medical Technologies by 79.0% during the second quarter. Jennison Associates LLC now owns 134,272 shares of the company’s stock worth $2,226,000 after purchasing an additional 59,272 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after purchasing an additional 285,579 shares during the period.

Kestra Medical Technologies Stock Performance

Shares of KMTS opened at $25.25 on Thursday. The company has a market capitalization of $1.47 billion and a price-to-earnings ratio of -7.97. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average price of $25.61 and a 200 day moving average price of $23.98.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.